Reviews in Endocrine and Metabolic Disorders

, Volume 10, Issue 3, pp 205–214 | Cite as

Pharmacotherapy in pediatric obesity: Current agents and future directions

Article

Abstract

Childhood obesity is emerging as a major public health threat, with adverse implications on the health of individuals and long-term costs to society. Family-based lifestyle interventions with behavioral modification, diet and exercise form the mainstay of treatment. Pharmacologic treatment may be considered in selected subjects, especially in the presence of significant and severe comorbidities, when lifestyle intervention has failed to achieve weight reduction. Orlistat and sibutramine are FDA-approved for treatment of pediatric obesity; metformin may be considered in the presence of clinically significant insulin resistance. Evidence is lacking on the appropriate duration of medical therapy and optimal combination with lifestyle intervention. Lack of coverage of medications by insurance and high out-of-pocket costs may be limiting factors to some families. Adverse effects necessitate careful monitoring and may lead to discontinuation of medication. Pharmacologic agents with novel mechanisms of action offer hope of improved efficacy, tolerability and safety.

Keywords

Pediatric obesity Pharmacotherapy Orlistat Sibutramine Metformin 

References

  1. 1.
    Ogden CL, Carroll MD, Curtin LR, et al. Prevalence of overweight and obesity in the United States, 1999–2004. JAMA. 2006;295:1549–55.CrossRefPubMedGoogle Scholar
  2. 2.
    Speiser PW, Rudolf MCJ, Anhalt H, et al. Consensus statement: childhood obesity. J Clin Endocrinol Metab. 2005;90:1871–87.CrossRefPubMedGoogle Scholar
  3. 3.
    Baker JL, Olsen LW, Sorensen TIA. Childhood body mass index and the risk of coronary heart disease in adulhood. N Engl J Med. 2007;357:2329–37.CrossRefPubMedGoogle Scholar
  4. 4.
    Bibbins-Domingo K, Coxson P, Pletcher MJ, et al. Adolescent overweight and future adult coronary heart disease. N Engl J Med. 2007;357:2371–9.CrossRefPubMedGoogle Scholar
  5. 5.
    Barlow SE, the Expert Committee. Expert Committee recommendations regarding the prevention, assessment and treatment of child and adolescent overweight and obesity: summary report. Pediatrics. 2007;120(4):S164–92.CrossRefPubMedGoogle Scholar
  6. 6.
    Ogden CL, Carroll MD, Flegal KM. High body mass index for age among US children and adolescents, 2003–2006. JAMA. 2008;299:2401–5.CrossRefPubMedGoogle Scholar
  7. 7.
    Spear BA, Barlow SE, Ervin C, et al. Recommendations for treatment of child and adolescent overweight and obesity. Pediatrics. 2007;120:S254–88.CrossRefPubMedGoogle Scholar
  8. 8.
    August GP, Caprio S, Fennoy I, et al. Prevention and treatment of pediatric obesity: an endocrine society clinical practice guideline based on expert opinion. J Clin Endocrinol Metab. 2008;93:4576–99.CrossRefPubMedGoogle Scholar
  9. 9.
    Sjostrom L, Rissanen A, Andersen T, et al. Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet. 1998;352:167–72.CrossRefPubMedGoogle Scholar
  10. 10.
    Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med. 2000;9:160–7.CrossRefPubMedGoogle Scholar
  11. 11.
    McDuffie JR, Calis KA, Uwaifo GI, et al. Three-month tolerability of orlistat in adolescents with obesity-related comorbid conditions. Obes Res. 2002;10:642–50.CrossRefPubMedGoogle Scholar
  12. 12.
    Norgren S, Danielsson P, Jurold R, et al. Orlistat treatment in obese prepubertal children: a pilot study. Acta Paediatr. 2003;92:666–70.CrossRefPubMedGoogle Scholar
  13. 13.
    McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004;17:307–19.PubMedGoogle Scholar
  14. 14.
    Ozkan B, Bereket A, Turan S, et al. Addition of orlistat to conventional treatment in adolescents with severe obesity. Eur J Pediatr. 2004;163:738–41.CrossRefPubMedGoogle Scholar
  15. 15.
    Maahs D, de Serna DG, Kolotkin RL, et al. Randomized, double-blind, placebo-controlled trial of orlistat for weight loss in adolescents. Endocr Pract. 2006;12:18–28.PubMedGoogle Scholar
  16. 16.
    Chanoine J-P, Hampl S, Jensen C, et al. Effect of orlistat on weight and body composition in obese adolescents: a randomized controlled trial. JAMA. 2005;293:2873–83.CrossRefPubMedGoogle Scholar
  17. 17.
    Godoy-Matos A, Carraro L, Vieira A, et al. Treatment of obese adolescents with sibutramine: a randomized, double-blind, controlled study. J Clin Endocrinol Metab. 2005;90:1460–5.CrossRefPubMedGoogle Scholar
  18. 18.
    Garcia-Morales LM, Berber A, Macias-Lara CC, et al. Use of sibutramine in obese Mexican adolescents: a 6-month, randomized, double-blind, placebo-controled, parallel-group trial. Clin Ther. 2006;28:770–82.CrossRefPubMedGoogle Scholar
  19. 19.
    Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805–12.CrossRefPubMedGoogle Scholar
  20. 20.
    Berkowitz RI, Fujioka K, Daniels SR, et al. Effects of sibutramine treatment in obese adolescents: a randomized trial. Ann Intern Med. 2006;145:81–90.PubMedGoogle Scholar
  21. 21.
    Freemark M, Bursey D. The effects of metformin on body mass index and glucose tolerance in obese adolescents with fasting hyperinsulinemia and a family history of type 2 diabetes. Pediatrics. 2001;107:E55.CrossRefPubMedGoogle Scholar
  22. 22.
    Kay JP, Alemzadeh R, Langley G, et al. Beneficial effects of metformin in normoglycemic morbidly obese adolescents. Metabolism. 2001;50:1457–61.CrossRefPubMedGoogle Scholar
  23. 23.
    Srinivasan S, Ambler GR, Baur LA, et al. Randomized, controlled trial of metformin for obesity and insulin resistance in children and adolescents: improvement in body composition and fasting insulin. J Clin Endocrinol Metab. 2006;91:2074–80.CrossRefPubMedGoogle Scholar
  24. 24.
    Burgert TS, Duran EJ, Goldberg-Gell R, et al. Short-term metabolic and cardiovascular effects of metformin in markedly obese adolescents with normal glucose tolerance. Pediatr Diabetes. 2008;9:567–76.CrossRefPubMedGoogle Scholar
  25. 25.
    Love-Osborne K, Sheeder J, Zeitler P. Addition of metformin to a lifestyle modification program in adolescents with insulin. J Pediatr. 2008;152:817–22.CrossRefPubMedGoogle Scholar
  26. 26.
    Gibson WT, Farooqi IS, Moreau M, et al. Congenital leptin deficiency due to homozygosity for the delta-133G mutation: report of another case and evaluation of response to four years of leptin therapy. J Clin Endocrinol Metab. 2004;89:4821–6.CrossRefPubMedGoogle Scholar
  27. 27.
    Carrel A, Moerchen V, Myers SE, et al. Growth hormone improves mobility and body composition in infants and toddlers with Prader-Willi syndrome. J Pediatr. 2004;145:744–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Lustig RH, Hinds PS, Ringwald-Smith K, et al. Octreotide therapy of pediatric hypothalamic obesity: a double-blind, placebo-controlled trial. J Clin Endocrinol Metab. 2003;88:2586–92.CrossRefPubMedGoogle Scholar
  29. 29.
    Despres J-P, Golay A, Sjostrom L, et al. Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med. 2005;353:2121–34.CrossRefPubMedGoogle Scholar
  30. 30.
    Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al. Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA. 2006;295:761–75.CrossRefPubMedGoogle Scholar
  31. 31.
    Moreira FA, Grieb M, Lutz B. Central side effects of therapies based on CB1 cannabinoid receptor agonist and antagonists: focus on anxiety and depression. Best Pract Res Clin Endocrinol Metab. 2009;23:133–44.CrossRefPubMedGoogle Scholar
  32. 32.
    Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol. 2000;15(Suppl 1):S22–6.CrossRefPubMedGoogle Scholar
  33. 33.
    Claudino AM, de Oliveira IR, Appolinario JC, et al. Double-blind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder. J Clin Psychiatry. 2007;68:1324–32.CrossRefPubMedGoogle Scholar
  34. 34.
    Gadde KM, Franciscy DM, Wagner HR, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA. 2003;289:1820–5.CrossRefPubMedGoogle Scholar
  35. 35.
    Kendall DM, Riddle MC, Rosenstock J, et al. Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. Diabetes Care. 2005;28:1083–91.CrossRefPubMedGoogle Scholar
  36. 36.
    DeFronzo RA, Ratner RE, Han J, et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005;28:1092–100.CrossRefPubMedGoogle Scholar
  37. 37.
    Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res. 2002;10:633–41.CrossRefPubMedGoogle Scholar
  38. 38.
    Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR versus placebo for weight loss in obese patients with depressive symptoms. Obes Res. 2002;10:1049–56.CrossRefPubMedGoogle Scholar
  39. 39.
    McGovern L, Johnson JN, Paulo R, et al. Treatment of pediatric obesity: a systematic review and meta-analysis of randomized trials. J Clin Endocrinol Metab. 2008;93:4600–5.CrossRefPubMedGoogle Scholar
  40. 40.
    Oude Luttikhuis H, Baur L, Jansen H, et al. Interventions for treating obesity in children. Cochrane Database Syst Rev. 2009;1:CD001872.PubMedGoogle Scholar
  41. 41.
    Uli N, Sundararajan S, Cuttler C. Treatment of childhood obesity. Curr Opin Endocrinol Diabetes Obes. 2008;15:37–47.PubMedGoogle Scholar
  42. 42.
    Freemark M. Pharmacotherapy of childhood obesity: an evidence-based, conceptual approach. Diabetes Care. 2007;30:395–402.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2009

Authors and Affiliations

  1. 1.Division of Pediatric Endocrinology, UH Rainbow Babies & Children’s HospitalCase Western Reserve UniversityClevelandUSA

Personalised recommendations